Report Highlights

India Neurorehabilitation Devices: Market Overview

India's neurorehabilitation devices market reached USD 312.6 million in 2024, shaped primarily by the country's escalating burden of neurological disease — an estimated 30 million Indians live with neurological disorders, with stroke alone accounting for over 1.8 million annual incidents according to the Indian Council of Medical Research. Government policy has been the dominant structural force, with the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Disease and Stroke (NPCDCS) directing district-level screening infrastructure that feeds demand for downstream rehabilitation. Private sector hospital chains such as Apollo Hospitals and Fortis Healthcare have led technology adoption in metro centres, deploying robotic gait trainers and functional electrical stimulation systems to differentiate premium neurology departments.

The market structure is bifurcated between an institutionalised metro segment — dominated by imported robotic therapy platforms from Ekso Bionics, Hocoma, and Bioness — and a fragmented non-metro segment served by lower-cost domestic and generic-import devices. Public sector health facilities account for roughly 38% of total device procurement, with the remainder split between corporate hospitals and specialist rehabilitation clinics. The entry of home-care and tele-rehabilitation platforms, accelerated by COVID-19 disruptions to in-patient services, has created a third structural tier that is beginning to attract venture investment and regulatory attention from the Central Drugs Standard Control Organisation (CDSCO).

Policy-Driven Growth in India's Neurorehabilitation Device Sector

Three specific policy mechanisms are directly translating into market expansion. First, the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY), which covers over 107 million families, has added procedure codes for neurological rehabilitation sessions, enabling public hospital reimbursement for device-assisted therapy. This code inclusion, formalised in the 2022 benefit package revision, directly increases the addressable patient base for device operators and therapy centres. Second, the Production Linked Incentive (PLI) Scheme for Medical Devices — administered by the Department of Pharmaceuticals under Notification S.O. 1269(E) — allocates INR 3,420 crore across five years to incentivise domestic manufacturing of Class C and D medical devices, a category that includes powered exoskeletons and neurostimulation implants. This has lowered the capital barrier for Indian OEMs entering the neurorehabilitation space.

Third, the National Health Policy 2017 mandates that rehabilitation services be integrated into district-level public health infrastructure by 2025, creating a hard procurement deadline that is compelling state health departments in Uttar Pradesh, Maharashtra, and Tamil Nadu to issue tenders for neurorehabilitation equipment. The Ministry of Health and Family Welfare's Rashtriya Bal Swasthya Karyakram (RBSK) programme additionally funds early neurological intervention devices for children under 18, creating a paediatric sub-segment previously absent from market planning. Collectively, these three mechanisms are generating an institutionally funded demand layer that supplements private hospital procurement and reduces market cyclicality.

Regulatory Barriers and Compliance Costs

The CDSCO, operating under the Medical Devices Rules 2017 (amended 2020), classifies active neurorehabilitation devices — including functional electrical stimulators and brain-computer interface headsets — as Class C or Class D, requiring mandatory clinical performance data, a conformity assessment by a CDSCO-notified body, and an import licence under Form MD-15. The average approval timeline for Class C devices is 18 to 24 months, compared to 8 to 12 months in the European Union under MDR 2017/745. This timeline disadvantage imposes a direct cost on multinational entrants: regulatory affairs teams estimate INR 60 to 90 lakh in compliance expenditure per device line before a single unit is sold, making India a deferred-entry market for mid-tier international manufacturers.

Local content requirements under the Public Procurement (Preference to Make in India) Order 2017, enforced by the Ministry of Commerce, mandate that government tenders above INR 200 crore must preference domestically manufactured medical devices where local supply meets quality criteria. For neurorehabilitation devices, this creates a structural disadvantage for fully imported systems in public procurement, as no import-only device automatically qualifies for the Class I preference category. Additionally, the Bureau of Indian Standards (BIS) IS 13450 series for electromedical equipment mandates conformity certification for powered rehabilitation systems, a process that adds three to six months and INR 8 to 15 lakh per product variant — a disproportionate burden on smaller domestic innovators attempting to scale.

Policy-Created Opportunities in India

The National Digital Health Mission (NDHM), rebranded as the Ayushman Bharat Digital Mission (ABDM) and operationalised through the National Health Authority, is creating a structured data infrastructure that neurorehabilitation device manufacturers can leverage for remote monitoring and longitudinal outcome tracking. Devices that integrate with the ABHA (Ayushman Bharat Health Account) ecosystem — enabling patient health record linkage — qualify for preferential procurement status in empanelled facilities under the AB-PMJAY network. This digital integration pathway is a policy-created commercial opportunity that device firms such as Meditek Systems are actively engineering into their product roadmaps, ahead of an anticipated CDSCO guideline on Software as a Medical Device (SaMD) expected in late 2025.

A second significant opportunity lies in the Scheme for Assistance to Disabled Persons for Purchase/Fitting of Aids and Appliances (ADIP Scheme), administered by the Ministry of Social Justice and Empowerment, which funds assistive and rehabilitation devices for persons with disabilities earning below INR 20,000 per month. The 2023-24 union budget increased ADIP allocation by 28% to INR 224 crore, with a specific sub-component for powered mobility and neurological rehabilitation aids. Device manufacturers that achieve ADIP empanelment gain access to a price-insensitive, government-funded patient cohort of approximately 2.68 crore beneficiaries — a distribution channel that eliminates standard hospital procurement competition and guarantees volume offtake at pre-negotiated rates.

Market at a Glance

Leading Market Participants

• Bioness Inc.
• Ekso Bionics
• ReWalk Robotics
• Hocoma AG
• Meditek Systems
• Siemens Healthineers India
• Philips India
• Reha Technology AG
• Fable Robotics
• Tata Medical and Diagnostics

Regulatory and Policy Environment

The primary legislative instrument governing neurorehabilitation devices in India is the Medical Devices Rules 2017, notified under the Drugs and Cosmetics Act 1940 and most recently amended via Gazette Notification G.S.R. 702(E) in September 2020. The CDSCO, functioning under the Directorate General of Health Services within the Ministry of Health and Family Welfare, is the central regulatory authority. Manufacturers must obtain a CDSCO licence under Form MD-9 (domestic) or Form MD-15 (import), with Class C device applications requiring a clinical investigation report compliant with IS 14385 or ISO 14155. A mandatory post-market surveillance report is due within 30 days of any serious adverse event, enforceable under Rule 30 of the Medical Devices Rules. India's framework is materially stricter than ASEAN peer markets such as Thailand and Indonesia, where Class B equivalents face lighter clinical evidence requirements — creating a relative cost disadvantage for India-first launch strategies.

Upcoming regulatory changes expected to reshape compliance burdens include the CDSCO's draft guidance on Software as a Medical Device, anticipated for formal notification in H2 2025, which will for the first time bring AI-enabled rehabilitation software platforms under mandatory licensing. The Quality Council of India (QCI), designated as a conformity assessment body, is expanding its audited laboratory network to reduce the average Class C device assessment time from the current 22 months to a target of 14 months by 2026, per Ministry commitments under the National Medical Devices Policy 2023. This policy, approved by the Union Cabinet in April 2023, sets a target of growing India's domestic medical device industry to USD 50 billion by 2030, with neurorehabilitation explicitly cited as a priority technology cluster — signalling sustained regulatory investment in the sector's infrastructure.

Long-Term Policy Outlook for India's Neurorehabilitation Device Sector

By 2032, the most consequential policy shift will be the full operationalisation of the National Medical Devices Policy 2023's cluster-based manufacturing mandate, which designates Andhra Pradesh's Vishakhapatnam Medical Device Park and Himachal Pradesh's Baddi cluster as priority zones for neurorehabilitation device production. Fiscal incentives under these clusters — including a 15% capital subsidy on plant and machinery and a five-year concessional electricity tariff — will structurally reduce domestic manufacturing costs, narrowing the price gap between Indian-made and imported robotic rehabilitation systems to below 20% by 2029. This cost convergence will accelerate public hospital procurement of domestically manufactured systems and compress margins for import-dependent distributors.

A second critical policy trajectory is the expected expansion of AB-PMJAY benefit packages to include home-based neurorehabilitation device rental reimbursement, a reform under active consideration by the National Health Authority as part of its 2025-27 strategic plan. If enacted, this reform will unlock a home-care device segment currently constrained by out-of-pocket affordability barriers — estimated at USD 78 million in suppressed demand by 2028. Simultaneously, India's ratification commitments under the UN Convention on the Rights of Persons with Disabilities will drive progressive tightening of accessibility mandates, compelling public infrastructure operators to procure certified rehabilitation devices. Together, these policy vectors ensure that government action — not private sector innovation cycles — will remain the dominant demand driver through the forecast horizon.

Market Segmentation

By Device Type

• Neurorobotic Systems
• Functional Electrical Stimulation Devices
• Transcranial Magnetic Stimulation Systems
• Brain-Computer Interface Devices
• Wearable Neurorehabilitation Devices
• Cognitive Rehabilitation Systems

By Application

• Stroke Rehabilitation
• Traumatic Brain Injury
• Spinal Cord Injury
• Parkinson's Disease
• Multiple Sclerosis
• Paediatric Neurological Disorders

By End User

• Public Hospitals
• Private Hospitals
• Rehabilitation Centres
• Home Care Settings
• Ambulatory Surgical Centres

By Technology

• Robotics-Assisted Therapy
• Neurostimulation
• Virtual Reality-Based Rehabilitation
• Tele-rehabilitation Platforms
• AI-Enabled Adaptive Therapy

Frequently Asked Questions

Q1. Which regulatory agency approves neurorehabilitation devices for sale in India? ▼

The Central Drugs Standard Control Organisation (CDSCO), under the Ministry of Health and Family Welfare, is the sole national authority responsible for licensing medical devices under the Medical Devices Rules 2017. Class C and Class D neurorehabilitation devices require a conformity assessment by a CDSCO-notified body before an import or manufacturing licence is granted.

Q2. How does the AB-PMJAY scheme affect device procurement in the neurorehabilitation market? ▼

The 2022 revision of the AB-PMJAY benefit package introduced reimbursement codes for device-assisted neurological rehabilitation sessions, directly enabling public hospital procurement of qualifying systems. Devices must be used in PMJAY-empanelled facilities and meet CDSCO Class C or D certification to qualify for reimbursement-linked procurement.

Q3. What does the Production Linked Incentive Scheme offer manufacturers of neurorehabilitation devices? ▼

The PLI Scheme for Medical Devices, notified under S.O. 1269(E), provides incremental financial incentives over five years on sales of domestically manufactured Class C and D devices, including powered exoskeletons and neurostimulation systems. Eligible manufacturers must meet minimum investment thresholds and demonstrate year-on-year production growth to continue receiving disbursements.

Q4. What is the expected timeline for CDSCO's Software as a Medical Device guidance to take effect? ▼

The CDSCO draft guidance on Software as a Medical Device is anticipated for formal gazette notification in the second half of 2025, bringing AI-enabled rehabilitation software under mandatory licensing for the first time. Existing software products already on the market will be subject to a transition compliance window, the duration of which has not yet been formally specified.

Q5. How do local content rules under the Make in India Order affect international device suppliers? ▼

The Public Procurement (Preference to Make in India) Order 2017 requires government tenders above INR 200 crore to preference domestically manufactured medical devices where local supply meets defined quality thresholds. International suppliers without Indian manufacturing or licensed domestic production partnerships are excluded from the Class I preference category in public hospital tenders.